-
Thematic Analysis
NewState of the Biopharmaceutical Industry 2024 Edition (Mid-Year Update) – Thematic Intelligence
Reasons to buy the ‘State of the Biopharmaceutical Industry 2024’ thematic intelligence report: Highlight the business environment and the industry, regulatory, and macroeconomic trends that are going to shape the biopharmaceutical industry in the next 12 months. Benchmark the impact of major themes on the biopharmaceutical industry in the next 12 months, Identify themes that will have the greatest positive or negative impact in the coming months. Comprehend the opinions of industry respondents on these themes. Predict the industry’s growth prospects...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AT-101 in Marginal Zone B-cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AT-101 in Marginal Zone B-cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AT-101 in Marginal Zone B-cell Lymphoma Drug Details: AT-101...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MRNA-2752 in Head And Neck Squamous Cell Carcinoma (HNSC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MRNA-2752 in Head And Neck Squamous Cell Carcinoma (HNSC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MRNA-2752 in Head And Neck Squamous...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MRNA-1405 in Norovirus Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MRNA-1405 in Norovirus Infections report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MRNA-1405 in Norovirus Infections Drug Details: mRNA-1405 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MRNA-1403 in Norovirus Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MRNA-1403 in Norovirus Infections report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MRNA-1403 in Norovirus Infections Drug Details: mRNA-1403 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MRNA-4157 in Gastric Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MRNA-4157 in Gastric Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MRNA-4157 in Gastric Cancer Drug Details: mRNA-4157 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MRNA-4157 in Pancreatic Ductal Adenocarcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MRNA-4157 in Pancreatic Ductal Adenocarcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MRNA-4157 in Pancreatic Ductal Adenocarcinoma Drug Details: mRNA-4157 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MRNA-4157 in Adenocarcinoma Of The Gastroesophageal Junction
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MRNA-4157 in Adenocarcinoma Of The Gastroesophageal Junction report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MRNA-4157 in Adenocarcinoma Of The Gastroesophageal Junction Drug...
-
Product Insights
NewNet Present Value Model: Moderna Inc’s mRNA-1647
Empower your strategies with our Net Present Value Model: Moderna Inc's mRNA-1647 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Moderna Inc’s mRNA-3927
Empower your strategies with our Net Present Value Model: Moderna Inc's mRNA-3927 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.